MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Olfactory discrimination differentiate drug-induced parkinsonism and Parkinson’s disease

    IH. Kwak, JJ. Lee, MS. Kim, SY. Kang, HI. Ma, YE. Kim (Anyang-si, Republic of Korea)

    Objective: In this study, we evaluated detailed differential features of olfactory function in PD and DIP. Background: DIP is common but it is challenging to…
  • 2023 International Congress

    The role of genetic testing in Dystonia diagnosis

    C. Guedes Vaz, J. Moura, D. Costa, A. Sardoeira, M. Magalhães (Porto, Portugal)

    Objective: To determine the contribution of different approaches to the clinical use of genetic tests in dystonia diagnosis. Background: Dystonias are a heterogeneous group of…
  • 2023 International Congress

    Differences in patients with Impulse Control Disorder based on antiparkinsonian drug treatment in a Mexican Institute.

    LG. Lira Juárez, AJ. Hernández-Medrano, MF. Medina Pérez, DP. Romero-Terán, MA. Ruiz Mafud, MAG. Medrano Delgado, AY. Regalado Mustafá, K. Talavera Lagunas, EC. Santiago Delacruz, G. Hernandez Armesto, DR. Aguila Godinez, AA. Herrera Ruiz, GI. Cerda Hernández, A. Abundes-Corona, A. Cervantes-Arriaga, M. Rodríguez-Violante, A. Alcocer Salas, JF. García Hernandez, A. Domínguez García (Mexico, Mexico)

    Objective: To describe the differences in multiple factors based on Parkinson's treatment in patients with impulse control disorder Background: In intermediate-advanced phases of PE, psychiatric…
  • 2023 International Congress

    A novel THAP1 variant presenting with early-onset generalized dystonia in a family

    A. Dellert, B. Rodrigues, N. Prakash (Farmington, USA)

    Objective: To report a novel mutation in the THAP1 gene presenting with childhood-onset generalized dystonia in a family. Background: DYT6 or DYT-THAP1 is a genetic…
  • 2023 International Congress

    Assessing Gait Disturbances in Parkinson’s Disease Using Multi-Spectral Diffusion Weighted Imaging

    I. Shelley, I. Ailes, M. Syed, K. Shivok, J. Miao, L. Krisa, F. Mohamed, R. Sergott, T. Liang, A. Sharan, M. Kogan, C. Wu, M. Alizadeh, O. Shoraka (Philadelphia, USA)

    Objective: We aimed to use diffusion MRI quantitative maps as an objective, non-invasive measure to assess for gait disturbances in Parkinson’s Disease (PD). Background: PD…
  • 2023 International Congress

    Association Between Anticholinergic Burden, MCI, and Cholinergic Denervation

    R. Paalanen, S. Roytman, P. Kanel, N. Bohnen (Ann Arbor, USA)

    Objective: To characterize the relationship between anticholinergic burden (ACB), mild cognitive impairment (MCI), and its underlying cholinergic pathology. Background: MCI is a common phenomenon in…
  • 2023 International Congress

    Sacral Mass Lesion Mimicking Atypical Foot Dystonia In Parkinsonian Patient

    B. Barton (CHICAGO, USA)

    Objective: Describe an unusual presentation of leg posturing and dystonic features in a patient with diagnosis of atypical parkinsonism, which was ultimately found to be…
  • 2023 International Congress

    Impact of non-pharmacological strategies on progression in Parkinson’s Disease and Cognitive Impairment.

    MAG. Medrano-Delgado, DR. Aguila-Godinez, MF. Ruiz-Mafud, LG. Lira-Juárez, EC. Santiago Delacruz, A. Domínguez-García, AJ. Hernández-Medrano, AY. Regalado-Mustafá, MF. Medina-Pérez, G. Hernandez-Armesto, K. Talavera-Laguna, A. Herrera-Ruiz, J. García-Hernández, DP. Romero-Terán, A. Alcocer-Salas, G. Cerda-Hernández, A. Abundes-Corona, M. Rodríguez-Violante, A. Cervantes-Arriaga (Ciudad de Mexico, Mexico)

    Objective: to determine the Impact of non-pharmacological strategies on progression in Parkinson's Disease and Cognitive Impairment. Background: PD is the second most common neurodegenerative disorder,…
  • 2023 International Congress

    18F-Florzolotau PET Imaging Captures the Distribution Patterns and Regional Vulnerability of Tau Pathology in Progressive Supranuclear Palsy

    FT. Liu, JY. Lu, XY. Li, YM. Sun, JJ. Wu, TC. Yen, QH. Zhao, CT. Zuo, J. Wang (Shanghai, China)

    Objective: This study aimed to investigate whether 18F-Florzolotau PET imaging may capture the distribution patterns and regional vulnerability of tau pathology in PSP, and to…
  • 2023 International Congress

    Agreement between Parkinson disease Home Diary and observer assessments before and after structured patient training

    C. Janz, J. Timpka, M. Löhle, A. Bremer, F. Gandor, G. Ebersbach, A. Storch, P. Odin (Lund, Sweden)

    Objective: The study aim was to investigate the effect of structured training concerning motor fluctuations on the agreement between observer and HD ratings and daily…
  • « Previous Page
  • 1
  • …
  • 91
  • 92
  • 93
  • 94
  • 95
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #25179 (not found)
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • Decision-making process for opicapone’s bedtime regimen
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley